come on, who care about panelist vote? FDA is just playing in democracy game. Guess why FDA never call panel for MNKD AFREZZA? They know how panel will vote for this innovative MNKD drug: 13:0 for approval. Diabetics need fast-acting post-prandial insulin because even short periods of high sugar in blood are very harmful. OREX will get CRL because there is already a line of companies with CRL. If OREX prove that Contrave is safest and most effective among this line so it will be a winner. FDA will inspire a competition among these 3 and the winner will get prize (approval).